Clover Health Investments, Corp.
CLOVNASDAQHealthcare● Active
$3.91
+$0.08(+1.96%)
Market Cap$2.0B
P/E Ratio—
52W High$4.23
52W Low$1.58
Clover Health Investments, Corp. (CLOV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLOV · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.07
Est. $0.07 · +0.0%
Revenue
$0.75B
Est. $0.71B · +4.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
CLOV reports quarterly as a NASDAQ-listed Medical - Healthcare Plans company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.05 | — | — | — | $0.73B | — |
| — Q2 FY2026 | May 6, 2026 | $0.07 | $0.07 | +0.0% | $0.75B | $0.71B | +4.8% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.10 | -$0.05 | +51.0% | $0.49B | $0.47B | +4.4% |
| ▼ Q4 FY2025 | Nov 4, 2025 | $0.02 | -$0.05 | -350.0% | $0.50B | $0.47B | +6.3% |
| — Q3 FY2025 | Aug 5, 2025 | $0.03 | $0.03 | +0.0% | $0.48B | $0.47B | +2.0% |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.07 | $0.05 | +171.4% | $0.46B | $0.47B | -1.0% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.07 | -$0.04 | +42.9% | $0.34B | $0.35B | -3.0% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.01 | -$0.02 | -50.0% | $0.33B | $0.35B | -4.9% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026
EPS Actual
$0.07
EPS Est.
$0.07
EPS Surpr.
+0.0%
Revenue
$0.75B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.05
EPS Est.
-$0.10
EPS Surpr.
+51.0%
Revenue
$0.49B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.05
EPS Est.
$0.02
EPS Surpr.
-350.0%
Revenue
$0.50B
Q3 FY2025
Aug 5, 2025
EPS Actual
$0.03
EPS Est.
$0.03
EPS Surpr.
+0.0%
Revenue
$0.48B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.05
EPS Est.
-$0.07
EPS Surpr.
+171.4%
Revenue
$0.46B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.07
EPS Surpr.
+42.9%
Revenue
$0.34B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-50.0%
Revenue
$0.33B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q3 FY2028 | $0.01 | $0.01 | $0.01 | 1 |
| Q2 FY2028 | $0.09 | $0.09 | $0.09 | 1 |
| Q1 FY2028 | $0.09 | $0.09 | $0.09 | 1 |
| Q4 FY2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q3 FY2027 | $-0.00 | $-0.00 | $-0.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.9B | $0.9B | $0.9B | 1 |
| Q3 FY2028 | $0.9B | $0.9B | $0.9B | 1 |
| Q2 FY2028 | $0.9B | $0.9B | $0.9B | 1 |
| Q1 FY2028 | $0.9B | $0.9B | $0.9B | 1 |
| Q4 FY2027 | $0.8B | $0.8B | $0.8B | 1 |
| Q3 FY2027 | $0.8B | $0.8B | $0.8B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +0.0% | $2.61 | $2.68 | +2.68% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +51.0% | $2.09 | $2.15 | +2.87% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -350.0% | $3.68 | $3.52 | -4.35% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +0.0% | $2.88 | $2.85 | -1.04% |
| ▲ Q2 FY2025 | May 6, 2025 | +171.4% | $3.35 | $3.35 | +0.00% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +42.9% | $4.32 | $4.14 | -4.17% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -50.0% | $4.32 | $4.35 | +0.69% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +120.0% | $1.67 | $1.88 | +12.57% |
Q2 FY2026+2.68%
Report Date
May 6, 2026
EPS Beat/Miss
+0.0%
Price Before
$2.61
Price After
$2.68
Q1 FY2026+2.87%
Report Date
Feb 26, 2026
EPS Beat/Miss
+51.0%
Price Before
$2.09
Price After
$2.15
Q4 FY2025-4.35%
Report Date
Nov 4, 2025
EPS Beat/Miss
-350.0%
Price Before
$3.68
Price After
$3.52
Q3 FY2025-1.04%
Report Date
Aug 5, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.88
Price After
$2.85
Q2 FY2025+0.00%
Report Date
May 6, 2025
EPS Beat/Miss
+171.4%
Price Before
$3.35
Price After
$3.35
Q1 FY2025-4.17%
Report Date
Feb 27, 2025
EPS Beat/Miss
+42.9%
Price Before
$4.32
Price After
$4.14
Q4 FY2024+0.69%
Report Date
Nov 6, 2024
EPS Beat/Miss
-50.0%
Price Before
$4.32
Price After
$4.35
Q3 FY2024+12.57%
Report Date
Aug 5, 2024
EPS Beat/Miss
+120.0%
Price Before
$1.67
Price After
$1.88
Avg Beat Reaction+2.15%
Avg Miss Reaction-1.83%
Beat Rate6 / 8 quarters
Largest Move+12.57% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLOV ends December
Clover Health Investments, Corp. (CLOV) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.07 (in line with the analyst consensus of $0.07). CLOV has beaten EPS estimates for 2 consecutive quarters. The next CLOV earnings date is expected around September 1, 2026.
Each quarter, investors track CLOV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLOV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLOV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLOV earnings · 4 questionsClover Health Investments, Corp.'s next earnings report is expected around September 1, 2026. CLOV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLOV historically reports after market close (AMC).
CLOV earnings datewhen is CLOV earningsCLOV next earnings datewhen does CLOV report earningsCLOV earnings calendar
▸ Source: FMP · Clover Health Investments, Corp. SEC filings · US GAAP · Clover Health Investments, Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026